Does Acetyl octapeptide-3 work?
Not properly: one study of 24 people, using a product that mixed it with other ingredients.
The only peer-reviewed human study found that tests a product containing SNAP-8 is a 2024 split-face study in 24 people, in which a microneedle patch carrying SNAP-8 together with other actives was compared with a plain hyaluronic acid patch for 28 days. SNAP-8 has not been tested on its own against placebo, and the claim that it beats Argireline comes from the manufacturer. That is grade C. 4
The one controlled clinical study of a product containing SNAP-8 appeared in Annals of Dermatology in 2024. The patch maker published it. Twenty-four healthy adults wore a dissolving microneedle patch under one eye overnight. It carried SNAP-8, a vitamin C derivative and a lipid signalling molecule. Under the other eye they wore a plain hyaluronic acid patch. Over 28 days the side with the active patch improved more in eye wrinkles and skin elasticity. There were no adverse effects. The microneedles push the ingredients through the outer skin layer. So the result says nothing about SNAP-8 in an ordinary cream. The mixture also means no one can credit the effect to SNAP-8 alone. 4
No independent trial has tested SNAP-8 alone against placebo. No head-to-head comparison with Argireline has been published. No study has followed users for longer than a few weeks. 4
Evidence checklist
- Randomised controlled trial One 2017 randomized study, size unconfirmed
- Human study over 100 people Sample size not confirmed in the article
- More than one research group Mostly manufacturer data
- Clinical outcomes, not surrogate markers Appearance of wrinkles only, not clinical
- Human safety data beyond case reports No published safety assessment
Read the full Acetyl octapeptide-3 page
More on Acetyl octapeptide-3
Citations
- Wang 2013, Am J Clin Dermatol: argireline (acetyl hexapeptide-8) for peri-orbital wrinkles, randomized placebo-controlled study doi.org
- FDA: how cosmetics are regulated but not approved fda.gov
- FDA: is it a cosmetic, a drug, or both? fda.gov
- Shin 2024, Ann Dermatol: dissolving microneedle patch containing acetyl octapeptide-3, split-face placebo-controlled study pubmed.ncbi.nlm.nih.gov
Reference information only, not medical advice. Drawn from the Acetyl octapeptide-3 article, fact-checked against the cited sources. No dosing anywhere on this site.